On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
ORGANIZATION
FPMAJ Urges More Precise Handling of CEA Price Tweaks for Products with “Cost Increase” Profile
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) is calling on the government to distinguish the handling under the cost-effectiveness assessment (CEA) scheme between products deemed to have no additional benefits versus comparators and those for which an evaluation…
To read the full story
Related Article
- It’s Time to Revise G1 Withdrawal Scheme, Rule Likely to Be Applied to Only a Few Products: FPMAJ
June 14, 2022
- 4-Year Grace Period Was Good News, but More Should Be Done for Re-Pricing Exclusion: FPMAJ
June 13, 2022
- FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
ORGANIZATION
- Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
April 10, 2024
- JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
- New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
April 8, 2024
- Generic Rate Hits Record for 6th Straight Quarter in October-December: JGA
April 8, 2024
- PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…